Interview with Ellen Velisek, RN, BSN, OCN: Patient Coordination Following CAR T-Cell Therapy

Interview with Ellen Velisek, RN, BSN, OCN: Preparing Patients for CAR T-Cell Therapy

The Evolving Field of CAR T-Cell Therapy

Welcome to the CAR T-Cell Therapy Resource Center! Here you’ll find current information, news items, highlights from the literature, case studies, and other resources that focus on CAR T-cell therapies and the advanced practitioner’s role in delivering high-quality care to our patients. If you have any feedback or questions, please contact jadpro-editor@conexiant.com.

Meredith Beaton, MSN, AGACNP-BC Assistant Professor of Medicine
Associate Vice Chair for APP Development & Mentorship
Medical Director, Inpatient BMT Program
University of Colorado School of Medicine

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

CAR T-Cell Therapy Resource Center

Interview with Ellen Velisek, RN, BSN, OCN: Patient Coordination Following CAR T-Cell Therapy

ASTCT: CAR-T Toxicity Grading and Management

ASTCT NucleusPlus: Insights on Emerging CAR-T Therapies

American Cancer Society Patient Lodging Programs

ASH OnDemand: CAR T-Cell Therapy Consults—Navigating a New Landscape

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Blood

How I treat HLH-like toxicities following immune effector cell therapy

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Translational Oncology

Development and characterization of anti-CXCR4 chimeric antigen receptor T cells

Blood Advances

CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review

Journal of Medical Economics

Time to access matters: Patient gains from faster CAR T-cell reimbursement in Europe

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Fast Facts #12: BCMA Targets